Other Clinical Trial - Omics Techniques in Fatty Liver Disease

Status Not yet recruiting

Clinical Trial Summary

Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in Western countries and one of the leading causes of liver transplantation in the world. Its spectrum ranges from simple steatosis to decompensated cirrhosis, resulting from progressive fibrosis due to inflammation and cellular injury. The reasons why patients with the same degree of steatosis have different evolutions are not sufficiently known. The objective of this project is to identify biomarkers that predict disease progression, using omics techniques, which can serve to develop new therapeutic strategies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Fatty Liver
Liver Diseases
Non-Alcoholic Fatty Liver Disease

Clinical Trial Details

NCT number	NCT05907408
Study type	Observational [Patient Registry]
Source	Universidade Federal do Rio de Janeiro
Contact	Guilherme FM Rezende, MD PhD
Phone	55+21999976292
Email	guimottarezende@gmail.com
Status	Not yet recruiting
Phase
Start date	July 1, 2023
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05480696` - Soluble Fibre Supplementation in NAFLD	Phase 1
Active, not recruiting	`NCT02500147` - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)	Phase 4
Completed	`NCT04671186` - Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan	N/A
Recruiting	`NCT05979779` - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis	Phase 2
Recruiting	`NCT05462353` - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH	Phase 2
Completed	`NCT05006885` - ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)	Phase 1
Completed	`NCT04117802` - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome	N/A
Recruiting	`NCT04365855` - The Olmsted NAFLD Epidemiology Study (TONES)	N/A
Recruiting	`NCT05618626` - Prevention of NAFLD and CVD Through Lifestyle Intervention	N/A
Completed	`NCT03256526` - 6-week Safety and PD Study in Adults With NAFLD	Phase 2
Enrolling by invitation	`NCT06152991` - Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy	Phase 3
Completed	`NCT03681457` - Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects	Phase 1
Completed	`NCT06244550` - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors	N/A
Not yet recruiting	`NCT05120557` - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH	N/A
Completed	`NCT03060694` - Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
Completed	`NCT02526732` - Hepatic Inflammation and Physical Performance in Patients With NASH	N/A
Recruiting	`NCT01988441` - The Influence of Autophagy on Fatty Liver
Recruiting	`NCT01680003` - Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease	Phase 2
Completed	`NCT01712711` - Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease	Phase 2
Recruiting	`NCT00941642` - Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease	Phase 4